This prospective subanalysis of the phase III EMN02/HO95 trial suggests benefit in PFS and OS with double ASCT, particularly for patients with high-risk MM.
The use of KRd induction plus transplantation and consolidation resulted in a CR or better in approximately 75% of patients with high-risk smoldering myeloma with an acceptable safety profile.
BCMA-CART with or without cyclophosphamide lymphodepletion demonstrates promising clinical activity in heavily pretreated patients with MM.
Combined infusion of CD19- and BCMA-specific CAR T-cells generally well tolerated and produces high remission rates in patients with relapsed/refractory multiple myeloma.
Daratumumab monotherapy demonstrated clinical activity and a favorable safety profile in patients with intermediate- and high-risk smoldering multiple myeloma.
Extended follow-up continues to demonstrate significant increase in PFS with addition of daratumumab to lenalidomide/dexamethasone for patients with relapsed/refractory myeloma.
Results from the dose escalation show that second-generation bb2121 CAR T-cell therapy yielded a 94% ORR and a 56% CR rate in heavily pretreated patients with relapsed/refractory MM.
A new human scFv-derived BCMA-targeted CAR T-cell appears tolerable with no reported dose-limiting toxicity and preliminary evidence of activity in patients with heavily pretreated myeloma.
In evaluable patients who relapsed following initial RVD therapy (with or without upfront ASCT), 4 cycles of PCD yielded an ORR of 85% with 95% of transplant-naive patients proceeding to a first ASCT.
The use of manual subcutaneous injection of coformulation of daratumumab and rHuPH20 enabled short administration, was well tolerated, and demonstrated a response rate similar to IV daratumumab.
Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.
Among patients with newly diagnosed MM not undergoing ASCT, ixazomib-based induction followed by ixazomib maintenance therapy was associated with an ORR of 94%, including a CR rate of 35%.
In this online course, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the results and provide their perspective on the clinical applicability of key multiple myeloma studies presented at the Hematology 2017 annual meeting.
The combination of daratumumab plus VMP reduced the risk of progression or death by 50% vs VMP alone in transplantation-ineligible patients with newly diagnosed myeloma in this randomized, open-label phase III study.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.